Lapatinib
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Lapatinib: From an Unrecorded Original Indication to Dermatofibrosarcoma Protuberans
One-Sentence Summary
The evidence pack for Lapatinib (DrugBank DB01259) does not contain the original approved indication or mechanism of action — both are recorded as data gaps. The TxGNN model predicts a possible new indication for Dermatofibrosarcoma Protuberans (DFSP), but this prediction is currently supported by no clinical trials and no published literature, and the drug is not marketed in Norway.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no Norway license records and original_indications is empty in the evidence pack |
| Predicted New Indication | Dermatofibrosarcoma Protuberans |
| TxGNN Prediction Score | 99.30% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for lapatinib is not available in this evidence pack, and no original indication is recorded either, so a direct mechanistic bridge between the original use and DFSP cannot be established from the data provided.
Based on general knowledge encoded in the model's rationale, DFSP is driven primarily by a COL1A1-PDGFB fusion that causes constitutive PDGFRB activation, and its standard targeted therapy is imatinib (a PDGFR inhibitor). Lapatinib's known targets — EGFR and HER2 — do not directly overlap with PDGFRB. The proposed link relies only on a theoretical, unconfirmed possibility of off-target PDGFR cross-inhibition, with no experimental or clinical data to support it.
Given the missing MOA data and the absence of a validated original indication, the mechanistic plausibility of this prediction is weak and should be treated as hypothesis-generating only, not as evidence of therapeutic relevance.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Norway Market Information
Lapatinib currently holds no market authorization in Norway (0 licenses on file; market status: not marketed).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high, but there is zero clinical trial or literature support, the mechanistic rationale linking lapatinib (EGFR/HER2 inhibitor) to DFSP (PDGFRB-driven) is weak and speculative, and critical drug-level data (MOA, TFDA/label warnings and contraindications) are missing — one of which (label warnings/contraindications) is flagged as a Blocking data gap that prevents even an initial S1 safety assessment.
To proceed, the following is needed:
- Original indication and label data for lapatinib (currently entirely absent from the evidence pack)
- Mechanism of action data (DG002) to properly evaluate the EGFR/HER2–PDGFRB rationale gap
- TFDA/Norway label warnings and contraindications (DG001, Blocking) before any safety review can begin
- At minimum, preclinical or case-level evidence connecting HER2/EGFR inhibition to DFSP biology before advancing beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.